41- Plasma Aβ42 as Biomarker of Prodromal Alzheimer’s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study.

J Alzheimers Dis. 2018 Aug 20. doi: 10.3233/JAD-180321.